{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:22:02Z","timestamp":1770135722233,"version":"3.49.0"},"reference-count":30,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,11,1]]},"abstract":"<jats:p>Most cases of adult-onset (AO) GH deficiency (GHD) result from the presence of hypothalamo-pituitary tumors or their treatment. GH replacement is now widely used in adults with hypopituitarism, but its effect on hypothalamo-pituitary tumor growth or recurrence is unknown. Anecdotal evidence from early experience of GH replacement in adults documented occasional tumor recurrence, but any relationship of this to the use of GH was unclear. We have now prospectively imaged the pituitary glands of 100 consecutive patients (60 females, 40 males; mean age, 46 yr; range, 18\u201369 yr) who had AO-GHD after appropriate treatment for a pituitary or peripituitary tumor. External radiotherapy had been given to 91 patients. All patients were treated with a dose titration regimen to maintain serum IGF-I between the median and upper end of the age-related reference range. Pituitary imaging was performed before the commencement of GH and after 6 and 12 months of treatment in all patients, again at 2 yr in 92 patients, at 3 yr in 63 patients, and after 4 yr in 23 patients. In only one patient was there evidence of slight intrasellar tissue enlargement at 6 months; GH replacement was continued, and there was no further change between 6 and 12 months. In all other patients, either the appearances were unchanged or the amount of tissue was reduced during long-term follow-up on GH. We have shown that hypothalamo-pituitary tumor recurrence was thus very rare over this time period in this group of GH-treated patients, and this is reassuring. Similar prospective longitudinal observation of patients who have not received postoperative irradiation and comparison with rates of tumor recurrence in control series are desirable.<\/jats:p>","DOI":"10.1210\/jcem.86.11.8018","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:06:35Z","timestamp":1389200795000},"page":"5172-5175","source":"Crossref","is-referenced-by-count":33,"title":["Hypothalamo-Pituitary Surveillance Imaging in Hypopituitary Patients Receiving Long-Term GH Replacement Therapy"],"prefix":"10.1210","volume":"86","author":[{"given":"Giovanni","family":"Frajese","sequence":"first","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Drake","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela A.","family":"Loureiro","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Evanson","sequence":"additional","affiliation":[{"name":"Diagnostic Imaging (J.E.), St. Bartholomew\u2019s Hospital, London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Coyte","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana F.","family":"Wood","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley B.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Michael","family":"Besser","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Monson","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology (V.F., W.M.D., R.A.L., D.C., D.F.W., A.B.G., G.M.B., J.P.M.), London EC1A 7BE, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071617480423500_R1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(89)92328-3","article-title":"Beneficial effects of growth hormone treatment in GH-deficient adults.","volume":"1","author":"J\u00f8rgensen","year":"1989","journal-title":"Lancet"},{"key":"2020071617480423500_R2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJM198912283212605","article-title":"The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.","volume":"321","author":"Salomon","year":"1989","journal-title":"N Engl J Med"},{"key":"2020071617480423500_R3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2265.1992.tb02287.x","article-title":"The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition.","volume":"37","author":"Binnerts","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480423500_R4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.1992.tb02901.x","article-title":"Growth hormone treatment of adults with growth hormone deficiency: results of a 13 month placebo-controlled cross-over study.","volume":"36","author":"Whitehead","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480423500_R5","first-page":"309","article-title":"Treatment of adults with growth hormone deficiency with recombinant human growth hormone.","volume":"76","author":"Bengtsson B-A\u030a, Eden","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480423500_R6","first-page":"143","article-title":"Individual susceptibility and GH dosing regimen in adults","author":"Drake","year":"1999","journal-title":"In: Monson JP, ed. Challenges in GH therapy. Oxford, UK: Blackwell Science;"},{"key":"2020071617480423500_R7","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1210\/jcem.83.11.5223","article-title":"Optimising growth hormone replacement therapy by dose titration in hypopituitary adults.","volume":"83","author":"Drake","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480423500_R8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2265.1999.00722.x","article-title":"Dose titration and patient selection increases the efficacy of GH replacement in GHD adults.","volume":"50","author":"Murray","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480423500_R9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1677\/jme.0.0020201","article-title":"A monoclonal antibody to human insulin-like growth factor-I: characterisation, use in radioimmunoassay and effect on the biological activities of the growth factor.","volume":"2","author":"Morrell","year":"1989","journal-title":"J Mol Endocrinol"},{"key":"2020071617480423500_R10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0026-0495(94)90245-3","article-title":"Serum lipid levels in growth hormone deficient men.","volume":"43","author":"De Boer","year":"1994","journal-title":"Metabolism"},{"key":"2020071617480423500_R11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.ATV.14.3.434","article-title":"High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults.","volume":"14","author":"Johansson","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"2020071617480423500_R12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/hrt.67.1.92","article-title":"Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality.","volume":"67","author":"Shahi","year":"1992","journal-title":"Br Heart J"},{"key":"2020071617480423500_R13","first-page":"153","article-title":"The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults.","volume":"80","author":"Weaver","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480423500_R14","first-page":"119","article-title":"The effects of low-dose recombinant human growth hormone on cardiovascular structure and function in hypopituitary growth hormone-deficient adults.","volume":"2","author":"Fort","year":"1995","journal-title":"Endocrinol Metab"},{"key":"2020071617480423500_R15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2265.1997.1911029.x","article-title":"Acromegaly, colonic polyps and neoplasia.","volume":"47","author":"Jenkins","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480423500_R16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"2020071617480423500_R17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","article-title":"Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.","volume":"351","author":"Hankinson","year":"1998","journal-title":"Lancet"},{"key":"2020071617480423500_R18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0140-6736(90)91812-O","article-title":"Premature mortality due to cardiovascular disease in hypopituitarism.","volume":"336","author":"Rose\u0301n","year":"1990","journal-title":"Lancet"},{"key":"2020071617480423500_R19","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1210\/jcem.85.11.6990","article-title":"Serum levels of insulin-like growth factor (IGF-I), IGF-II, IGF-binding protein-3 and prostate-specific antigen as predictors of clinical prostate cancer.","volume":"85","author":"Harman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480423500_R20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jnci\/90.12.911","article-title":"Insulin-like growth factor-I in relation to prostate cancer risk: a population-based, case-control study.","volume":"90","author":"Wolk","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2020071617480423500_R21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1126\/science.282.5387.199a","article-title":"IGF-I and prostate cancer.","volume":"282","author":"Schaefer","year":"1998","journal-title":"Science"},{"key":"2020071617480423500_R22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem.83.2.4594","article-title":"Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review.","volume":"83","author":"Carroll","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480423500_R23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0950-351X(95)80418-8","article-title":"Surgical management of pituitary adenomas.","volume":"9","author":"Laws Jr","year":"1995","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"2020071617480423500_R24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1097-0142(19910815)68:4<860::AID-CNCR2820680431>3.0.CO;2-4","article-title":"The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas.","volume":"68","author":"Comtois","year":"1991","journal-title":"Cancer"},{"key":"2020071617480423500_R25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2265.1999.00865.x","article-title":"Audit of selected patients with non-functioning pituitary adenomas treated without irradiation\u2014a follow-up study.","volume":"51","author":"Turner","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480423500_R26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2265.1998.00393.x","article-title":"Radiotherapy for non-functioning tumours.","volume":"48","author":"Gittoes","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480423500_R27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2265.1993.tb02137.x","article-title":"The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas.","volume":"38","author":"Brada","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480423500_R28","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/1097-0142(19890401)63:7<1308::AID-CNCR2820630714>3.0.CO;2-Y","article-title":"Late regrowth of pituitary adenomas after irradiation and\/or surgery.","volume":"63","author":"Grigsby","year":"1989","journal-title":"Cancer"},{"key":"2020071617480423500_R29","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/bmj.304.6838.1343","article-title":"Risk of second brain tumour following conservative surgery and radiotherapy of pituitary adenoma.","volume":"304","author":"Brada","year":"1992","journal-title":"Brit Med J"},{"key":"2020071617480423500_R30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00006123-199809000-00020","article-title":"Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas.","volume":"43","author":"Lillehei","year":"1998","journal-title":"Neurosurgery"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/11\/5172\/9169398\/jcem5172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/86\/11\/5172\/9169398\/jcem5172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:39:04Z","timestamp":1594957144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/86\/11\/5172\/2849247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,1]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.86.11.8018","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11,1]]}}}